




PHARMACEUTICAL 2020

NEKTAR THERAPEUTICS
Rank 106 of 358





RealRate

PHARMACEUTICAL 2020

NEKTAR THERAPEUTICS Rank 106 of 358



The relative strengths and weaknesses of NEKTAR THERAPEUTICS are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEKTAR THERAPEUTICS compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 38% points. The greatest weakness of NEKTAR THERAPEUTICS is the variable Other Revenues, reducing the Economic Capital Ratio by 10% points.

The company's Economic Capital Ratio, given in the ranking table, is 155%, being 119% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	1,421,550
Cost of Goods Sold	21,374
Intangible Assets	76,501
Liabilities, Current	353,893
Liabilities, Non-Current	146,052
Other Assets	414,306
Other Compr. Net Income	5,311
Other Expenses	613
Other Liabilities	72,020
Other Net Income	-19
Other Revenues	114,617
Property and Equipment	64,999
Research and Development	434,566
Selling, General and Administrative Expense	98,712

Output Variable	Value in 1000 USD
Assets	1,977,356
Liabilities	571,965
Expenses	555,265
Revenues	114,617
Stockholders Equity	1,405,391
Net Income	-440,667
Comprehensive Net Income	-438,012
Economic Capital Ratio	155%